The Europe and Middle East & Africa (MEA) culture test for healthcare-associated infections (HAIs) market is poised for steady growth over the coming decade, supported by increasing awareness of infection prevention, stringent healthcare regulations, and the growing demand for accurate microbiological diagnostics. The industry was valued at US$ 270.3 million in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 2.9% from 2024 to 2034, reaching more than US$ 371.3 million by the end of 2034. Growing investments in hospital infection control programs, antimicrobial resistance surveillance, and laboratory automation are expected to continue driving demand for culture-based diagnostic testing across hospitals, diagnostic laboratories, and research institutions.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86426

Market Overview

Healthcare-associated infections remain among the most significant challenges facing healthcare systems across Europe and the Middle East & Africa. These infections increase patient morbidity, mortality, hospital stay duration, and overall treatment costs, making effective diagnosis a critical priority. Culture testing continues to serve as the gold standard for identifying bacterial, fungal, and certain viral pathogens responsible for HAIs. Despite the emergence of molecular diagnostic technologies, healthcare professionals continue to rely on culture-based methods because of their ability to determine antimicrobial susceptibility, isolate pathogens, and support infection control strategies.

Government initiatives promoting patient safety, stricter hospital accreditation standards, and increased surveillance programs have significantly strengthened demand for microbiological culture testing. In addition, the growing prevalence of multidrug-resistant organisms has further highlighted the importance of culture tests in guiding targeted antibiotic therapies.

Market Size and Growth

The Europe and MEA culture test for HAIs market generated US$ 270.3 million in revenue during 2023. Continued expansion of healthcare infrastructure, increasing surgical procedures, aging populations, and rising hospitalization rates are expected to sustain market growth throughout the forecast period. Between 2024 and 2034, the market is anticipated to grow at a 2.9% CAGR, ultimately exceeding US$ 371.3 million by 2034.

While growth remains moderate compared with molecular diagnostics, culture testing maintains a critical position in clinical microbiology due to its diagnostic reliability, cost-effectiveness, and regulatory acceptance. Continuous improvements in automated culture systems, faster incubation technologies, and digital laboratory workflows are expected to enhance laboratory efficiency and support market expansion.

Market Segmentation

The market can be segmented based on test type, infection type, end user, and geography. Blood culture testing continues to represent one of the largest segments due to the increasing incidence of bloodstream infections and sepsis in hospitalized patients. Urine, respiratory, wound, and catheter-associated culture tests also account for significant demand as hospitals intensify infection monitoring efforts.

By end user, hospitals remain the dominant segment because of high patient volumes and the implementation of comprehensive infection control protocols. Diagnostic laboratories are also witnessing increasing demand as healthcare providers outsource microbiological testing to specialized facilities with advanced laboratory capabilities. Research institutions contribute to market development through antimicrobial resistance studies and clinical microbiology research.

Regional Analysis

Europe represents the largest regional market owing to its highly developed healthcare infrastructure, widespread adoption of standardized infection surveillance programs, and supportive regulatory framework. Countries including Germany, France, the United Kingdom, Italy, and Spain continue to invest heavily in hospital infection prevention initiatives, laboratory modernization, and antimicrobial stewardship programs.

The Middle East and Africa region is expected to experience gradual expansion during the forecast period. Healthcare investments across Gulf Cooperation Council countries, increasing hospital construction projects, expanding diagnostic laboratory networks, and improving access to advanced microbiology services are creating favorable growth opportunities. Meanwhile, several African countries are strengthening infectious disease surveillance systems with support from international healthcare organizations, further encouraging the adoption of culture testing technologies.

Competitive Landscape

The Europe and MEA culture test for healthcare-associated infections market remains moderately consolidated, with leading global diagnostic companies focusing on technological innovation, strategic collaborations, product portfolio expansion, and laboratory automation. Manufacturers continue investing in automated culture systems, antimicrobial susceptibility testing platforms, and integrated microbiology solutions to improve laboratory efficiency and diagnostic accuracy.

Prominent market participants include Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Steris Plc, Hologic, Inc., bioMérieux SA, F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Hardy Diagnostics, Bio-Rad Laboratories, Inc., Danaher Corporation, and SSI Diagnostica A/S. These companies continue to strengthen their competitive positions through research and development investments, regional expansion strategies, and partnerships with hospitals and diagnostic laboratories.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453